NCT01440920View on ClinicalTrials.gov

A Phase I Study of OCV-501 in Acute Myeloid Leukemia Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

March 31, 2013

Study Completion Date

July 31, 2013

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

OCV-501

subcutaneously administered once a week, 4 times at the dose of 0.3 mg

DRUG

OCV-501

subcutaneously administered once a week, 4 times at the dose of 1 mg

DRUG

OCV-501

subcutaneously administered once a week, 4 times at the dose of 3 mg

Trial Locations (1)

Unknown

National Cancer Center, Tokyo

Sponsors
All Listed Sponsors
lead

Otsuka Pharmaceutical Co., Ltd.

INDUSTRY